1 / 10

5 Pharma Giants Leading the Monoclonal

Nowadays, the race in the pharmaceutical industry has shifted from just being bigger in size and market value. Companies have realized the era of innovation and advance drug developments is around the corner. One of the key areas that is witnessing a surge is monoclonal antibodies. The future of medicine is being rewritten by mAbs and oncology breakthroughs.<br>More Info: https://clival.com/blog/9-pharma-giants-leading-the-monoclonal-antibody-with-fy24-25-revenue

ClivalDatabase
Download Presentation

5 Pharma Giants Leading the Monoclonal

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. 5 Pharma Giants Leading the Monoclonal Antibody with FY24-25 Revenue

  2. Introduction Nowadays, the race in the pharmaceutical industry has shifted from just being bigger in size and market value. Companies have realized the era of innovation and advance drug developments is around the corner. One of the key areas that is witnessing a surge is monoclonal antibodies. The future of medicine is being rewritten by mAbs and oncology breakthroughs.

  3. Johnson & Johnson • Country: USA • Last year revenue: $ 88.8 Billion Johnson & Johnson leads with unmatched diversification. Its portfolio spans oncology, immunology, and vaccines. The company’s mAb programs support steady growth across multiple therapeutic areas. J&J thrives by not relying on a single blockbuster. This broad footprint gives stability in volatile markets and positions it for long-term dominance.

  4. Roche • Country: Switzerland • Last year revenue: $ 65.3 Billion Roche is the oncology king. Drugs like Tecentriq and Perjeta anchor revenues, while immunology assets broaden its base. Next-gen mAbs push innovation beyond traditional therapies.

  5. Merck • Country: USA • Last year revenue: $ 64.2 Billion Merck thrives on one star—Keytruda. This immuno-oncology drug has reshaped the market, generating billions yearly. Expansion into new cancer types secures its continued growth.

  6. Pfizer • Country: USA • Last year revenue: $ 63.6 Billion Pfizer enjoyed record COVID revenues. Now it’s in reset mode. Oncology and inflammation drugs carry the weight while biologics pipelines rebuild momentum.

  7. Key Takeaways from the Top 5 Pharma Leaders Despite differences in geography and strategy, one theme dominates: monoclonal antibodies and oncology drive global pharma revenues in 2024. Johnson & Johnson leads through diversification. Roche and Merck dominate oncology. AbbVie bets on mAb-driven immunology. AstraZeneca, Novartis, Sanofi, and GSK balance portfolios with biologics, respiratory drugs, and biosimilars.

  8. Conclusion Monoclonal antibodies and oncology are the ones that are driving huge industry growth. Undoubtedly, these may turn out to be the key catalysts in the industry growth. As we have already seen, Johnson & Johnson’s, AbbVie, Roche and all the others are investing heavily on the biologics.

  9. WEBSITE : WWW.CLIVAL.COM WEBSITE : WWW.CLIVAL.COM WWW.LIFESCIENCEINTELLIPEDIA.COM WWW.LIFESCIENCEINTELLIPEDIA.COM WWW.CHEMXPERT.COM WWW.CHEMXPERT.COM • • LOCATION:- C-89, SECTOR-65 NOIDA-U.P. 201301 (INDIA) E-MAIL:- INFO@LIFESCIENCEINTELLIPEDIA.COM | SALES@LIFESCIENCEINTELLIPEDIA.COM PHONE:- +91-120-6631301-335 MOB NO:- +91-9990237670

More Related